ADVERTISEMENT
Biotechnology company Gilead Sciences Inc. said Thursday it will buy CV Therapeutics for about $1.4 billion as a wave of consolidation in the drug industry continues. ...more
March 13, 2009
Three days a week, Philip Audette sat in a cushy white chair at the St. Jude Rehab Center, a needle pumping HIV drugs into his arm. He talked and laughed with a dozen other patients, all in good health, all receiving drugs they didn't need. All for the money. ...more
December 24, 2008
Two HIV drugs approved last year for patients who have developed resistance to older drugs also work well with new patients, and with fewer troubling side effects than a widely used regimen, according to the drugs' manufacturers. ...more
October 27, 2008
ADVERTISEMENT
Advertisement
TBO.com - Tampa Bay Online ©2009 Media General Communications Holdings, LLC. A Media General company. Member Agreement | Privacy Statement | Work With Us